Description

FLAVEDON MR 35 MG

Indications

FLAVEDON MR 35 MG is primarily indicated for the management of chronic stable angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart muscle. This medication is often prescribed to patients who experience angina episodes triggered by physical exertion or emotional stress. Additionally, FLAVEDON MR may be utilized in certain cases of ischemic heart disease to improve overall cardiac function and enhance the quality of life in patients suffering from this condition.

Mechanism of Action

The active ingredient in FLAVEDON MR 35 MG is Trimetazidine, which is known to optimize cellular metabolism in heart tissues. Trimetazidine acts as a metabolic modulator, enhancing the efficiency of glucose utilization by the myocardium. This mechanism helps to maintain energy production in the heart under conditions of ischemia, thereby reducing the frequency and severity of angina attacks. By improving the heart’s tolerance to hypoxia and ensuring better oxygen utilization, FLAVEDON MR contributes to a decrease in angina symptoms.

Pharmacological Properties

FLAVEDON MR 35 MG is classified as a metabolic agent. It is absorbed rapidly after oral administration, with peak plasma concentrations typically reached within 1-2 hours. The drug exhibits a half-life of approximately 5-7 hours, allowing for sustained therapeutic effects when taken as prescribed. Trimetazidine is primarily metabolized in the liver and excreted through the kidneys, which underscores the importance of monitoring renal function in patients receiving this medication. Its pharmacokinetic profile supports once-daily dosing, making it a convenient option for patients managing chronic angina.

Contraindications

FLAVEDON MR 35 MG should not be used in patients with a known hypersensitivity to Trimetazidine or any of the excipients in the formulation. It is contraindicated in patients with Parkinson’s disease or other movement disorders, as the medication may exacerbate these conditions. Additionally, FLAVEDON MR is not recommended for use in individuals with severe renal impairment, as accumulation of the drug may lead to increased risk of adverse effects. Pregnant and breastfeeding women should also avoid this medication unless deemed absolutely necessary by a healthcare provider.

Side Effects

Common side effects associated with FLAVEDON MR 35 MG include dizziness, headache, and gastrointestinal disturbances such as nausea and abdominal pain. Some patients may experience skin reactions, including rash or pruritus. Rarely, the medication can lead to more serious side effects, such as movement disorders, including tremors or rigidity, particularly in those with pre-existing conditions. It is important for patients to report any unusual symptoms to their healthcare provider promptly to ensure appropriate management.

Dosage and Administration

The recommended dosage of FLAVEDON MR 35 MG for adults is one tablet taken orally once daily, preferably at the same time each day to maintain consistent blood levels of the medication. It is advisable to take the tablet with food to enhance absorption and minimize gastrointestinal discomfort. For elderly patients or those with renal impairment, dosage adjustments may be necessary based on individual tolerance and response to treatment. It is crucial for patients to adhere to the prescribed regimen and not to exceed the recommended dosage without consulting their healthcare provider.

Interactions

FLAVEDON MR 35 MG may interact with other medications, potentially altering their effectiveness or increasing the risk of adverse effects. Notably, caution should be exercised when combining this medication with other drugs that affect the central nervous system, as the risk of movement disorders may be heightened. Additionally, concurrent use with medications that impact renal function should be monitored closely. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions.

Precautions

Before initiating treatment with FLAVEDON MR 35 MG, it is essential for healthcare providers to conduct a thorough assessment of the patient’s medical history, particularly regarding any history of movement disorders or renal impairment. Regular monitoring of renal function is recommended during treatment, especially in elderly patients. Patients should be advised to avoid abrupt discontinuation of the medication, as this may lead to a rebound effect and exacerbation of angina symptoms. It is also important to counsel patients about the potential for dizziness and to avoid activities that require alertness until they know how the medication affects them.

Clinical Studies

Clinical studies have demonstrated the efficacy of FLAVEDON MR 35 MG in reducing the frequency of angina attacks and improving exercise tolerance in patients with stable angina pectoris. In a randomized controlled trial, patients receiving Trimetazidine showed a significant reduction in the number of angina episodes compared to those receiving a placebo. Furthermore, the medication was well-tolerated, with a favorable safety profile. Long-term studies have also indicated that FLAVEDON MR may contribute to improved quality of life and functional capacity in patients with ischemic heart disease.

Conclusion

FLAVEDON MR 35 MG is a valuable therapeutic option for patients suffering from chronic stable angina pectoris. Its unique mechanism of action as a metabolic modulator allows for improved cardiac efficiency and reduced angina symptoms. While generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Regular monitoring and adherence to prescribed dosages are crucial for optimizing treatment outcomes. As with any medication, a thorough discussion with a healthcare provider is recommended to ensure safe and effective use of FLAVEDON MR.